CSPC Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 25, 2026 Mar 13
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S Mar 06
CSPC Pharmaceutical Group Limited Announces Nintedanib Esilate Powder for Inhalation Obtains Clinical Trial Approval in China Jan 02
CSPC Pharmaceutical Group Limited to Report Q3, 2025 Results on Nov 20, 2025 Nov 11
CSPC Pharmaceutical Group Limited Announces Tacrolimus Extended-Release Capsules Obtain Drug Registration Approval Oct 14
CSPC Pharmaceutical Group Limited Announces SYH2070 Injection Obtains Clinical Trial Approval in the U.S Oct 10
Cspc Pharmaceutical Group Limited Announces Lecanemab Injection Obtains Approval from the National Medical Products Administration of the People's Republic of China Sep 25
CSPC Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 22, 2025 Aug 12
CSPC Pharmaceutical Group Limited Announces Change in Composition of Nomination Committee, Effect from 27 June 2025 Jun 29
CSPC Pharmaceutical Group Limited Announces Meloxicam Injection (III) Obtains Drug Registration Approval Jun 23
CSPC Pharmaceutical Group Limited Announces Cobamamide Capsules Obtains Drug Registration Approval Jun 06
CSPC Pharmaceutical Group Limited to Report Q1, 2025 Results on May 29, 2025 May 19
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval for Vonoprazan Fumarate Tablets May 12
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Apr 23
CSPC Pharmaceutical Group Limited Announces Oseltamivir Phosphate for Suspension Obtains Drug Registration Approval Apr 16
Cspc Pharmaceutical Group Limited Announces Sys6041 (Antibody-Drug Conjugate) Obtains Clinical Trials in the U.S Apr 14
CSPC Pharmaceutical Group Limited Announces SYH2046 Tablets Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Apr 12
CSPC Pharmaceutical Group Limited Announces JMT108 (BI-FDA) Obtains Clinical Trial Approval in the U.S Apr 08
CSPC Pharmaceutical Group Limited, Annual General Meeting, May 30, 2025 Mar 28
Cspc Pharmaceutical Group Limited Announces Sys6040 (Antibody-Drug Conjugate) Obtains Approval from the National Medical Products Administration of the People's Republic of China Mar 21
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Announces Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough Therapy Designation for the Treatment of PROC Mar 18
CSPC Pharmaceutical Group Limited Announces SYH2051 (Selective ATM Inhibitor) Obtains Approval in the U.S Mar 13
CSPC Pharmaceutical Group Limited Announces National Medical Products Administration of the People's Republic of China Approves JMT108 (BI-Focused Fusion Protein Drug) to Conduct Clinical Trials in China Mar 05
CSPC Pharmaceutical Group Limited Receives Breakthrough Therapy Designation by the National Medical Products Administration Feb 28
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Announces First Patient Dosed in Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 Feb 27
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2024 Final Results on Mar 28, 2025 Feb 25
CSPC Pharmaceutical Group Limited Announces SYH2059 Tablets Obtains Clinical Trial Approval in the U.S Feb 10
Cspc Pharmaceutical Group Limited Announces Sys6017 (Herpes Zoster Mrna Vaccine) Obtains Clinical Trial Approval Feb 07
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Announce Anti-Her2 Biparatopic Antibody-Drug Conjugate JSKN003 Receive Approval from the Center for Drug Evaluation of the National Medical Products Administration to Initiate A Phase III Clinical Study Feb 06
CSPC Pharmaceutical Group Limited Announces Regorafenib Tablets Obtains Drug Registration Approval Jan 20
CSPC Pharmaceutical Group Limited Provides Indicative Results for the Period of 1 January 2024 to 31 December 2024 Jan 17
CSPC Pharmaceutical Group Limited Announces SYS6043 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval in the U.S Jan 16
CSPC Pharmaceutical Group Limited Obtains Marketing Approval Granted by National Medical Products Administration Jan 14
CSPC Pharmaceutical Group Limited Announces SYS6041 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval Jan 10
CSPC Megalith Biopharmaceutical Co., Ltd. Grants Breakthrough Therapy Designation by the National Medical Products Administration Jan 02
CSPC Pharmaceutical Group Limited's Leuprorelin Extended-Release Injection (SYH9016) Obtains Clinical Trial Approval Dec 30
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval for SYH2062 Injection Dec 26
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20
CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024 Aug 21
CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jul 11
CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 25
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China May 18
CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024 May 16
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs May 15
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 Apr 28
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S Apr 27
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval Mar 23
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024 Mar 20
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration Jan 15
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA Dec 18
CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets Dec 12
CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China Dec 02
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 29
CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023 Nov 21
CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China Nov 18
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08
CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China Nov 04
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Oct 31
CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors Oct 26
CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA Sep 07
CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval Aug 30
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023 Aug 24
CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 12
Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161) Jun 30
CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Jun 27
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 13